Treatment With [90]Y-Ibritumomab Tiuxetan Versus no Treatment in Patients With Follicular Non Hodgkin Lymphoma (Stage III or IV) Having Achieved a Partial or Complete Remission After First Line Chemotherapy
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bayer
The study has previously been posted by Schering AG, Germany. Schering AG, Germany has been renamed to Bayer Schering Pharma AG, Germany.
Bayer Schering Pharma AG, Germany is the sponsor of the trial.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Non Hodgkin Lymphoma stage III or IV at timepoint of diagnosis
Patients who have achieved a remission after first line chemotherapy
No less than 6 weeks and no more than 12 weeks since last dose of chemotherapy
older than 18 years
written informed consent
You may not be if
Any other anticancer treatment for NHL except the preceding first line chemotherapy
Prior radiation therapy
Patients who have not recovered from the toxic effects of the first line chemotherapy
Any other cancer or history of cancer less than 10 years ago
Patients with known HIV positivity
patients with pleural effusion or ascites
female patients who are pregnant or breast feeding (women of childbearing potential must have a negative serum pregnancy test at study entry)
Adults not employing an effective method of birth control during study treatment and 12 months thereafter
Patients unable or unwilling to comply with protocol
Clareo Health | Treatment With [90]Y-Ibritumomab Tiuxetan Versus no Treatment in Patients With Follicular Non Hodgkin Lymphoma (Stage III or IV) Having Achieved a Partial or Complete Remission After First Line Chemotherapy
